Absci vs Seres Therapeutics
Absci is the larger business, with $2.8m of revenue in fiscal 2025 against $789,000 for Seres Therapeutics (3.5 times as much). Seres Therapeutics kept more of each dollar of sales as profit: a net margin of 721.9% against -4113.7%.
| Latest fiscal year | AbsciABSI, 2025 | Seres TherapeuticsMCRB, 2025 |
|---|---|---|
| Revenue | $2.8m | $789,000 |
| Revenue growth | -38.2% | — |
| Net income | −$115m | $5.7m |
| Operating margin | -4297.0% | — |
| Net margin | -4113.7% | 721.9% |
| Return on equity | -62.5% | 19.6% |
| Free cash flow | −$94.0m | $865,000 |
| Cash | $20.0m | $45.8m |
| Total debt | $873,000 | $0 |
| Debt to equity | 0.5% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 140 | 66 |
| Market value | $1.57bn | $18.9m |
| Price vs our value range | — | Below our value range |
| Moat score | 12 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 5 buys, 2 sales | 0 buys, 16 sales |